Low-flow ECCO₂R conjoined with renal replacement therapy platform to manage pulmonary vascular dysfunction with refractory hypercapnia in ARDS.

ABSTRACT:

Background

Hypercapnia worsens lung vascular dysfunction during acute respiratory distress syndrome (ARDS). We tested whether an extracorporeal carbon dioxide removal (ECCO₂R) device based on a renal replacement therapy platform (Prismalung®) may reduce PaCO₂ and alleviate lung vascular dysfunction in ARDS patients with refractory hypercapnia.

Methods

We planned to prospectively include 20 patients with moderate-to-severe ARDS, pulmonary vascular dysfunction on echocardiography, and PaCO₂ ≥ 48 mmHg despite instrumental dead space reduction and the increase in respiratory rate. Hemodynamics, echocardiography, respiratory mechanics, and arterial blood gases were recorded at 2 (H2), 6 (H6) and 24 (H24) hours as ECCO₂R treatment was co

SUBMITTER: Mekontso Dessap A 

PROVIDER: S-EPMC10788508 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature